196 related articles for article (PubMed ID: 16419112)
1. Fatal liver failure with the emergence of hepatitis B surface antigen variants with multiple stop mutations after discontinuation of lamivudine therapy.
Zhang JM; Wang XY; Huang YX; Yin YK; Guan S; Xu Y; Roggendorf M; Lu M
J Med Virol; 2006 Mar; 78(3):324-8. PubMed ID: 16419112
[TBL] [Abstract][Full Text] [Related]
2. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
Ohishi W; Shirakawa H; Kawakami Y; Kimura S; Kamiyasu M; Tazuma S; Nakanishi T; Chayama K
J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.
Natsuizaka M; Hige S; Ono Y; Ogawa K; Nakanishi M; Chuma M; Yoshida S; Asaka M
J Viral Hepat; 2005 Mar; 12(2):154-9. PubMed ID: 15720530
[TBL] [Abstract][Full Text] [Related]
4. Lamivudine resistance and other mutations in the polymerase and surface antigen genes of hepatitis B virus associated with a fatal hepatic failure case.
Bottecchia M; Ikuta N; Niel C; Araujo NM; O KM; Gomes SA
J Gastroenterol Hepatol; 2008 Jan; 23(1):67-72. PubMed ID: 18171343
[TBL] [Abstract][Full Text] [Related]
5. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance.
Hsu CW; Yeh CT; Chang ML; Liaw YF
Gastroenterology; 2007 Feb; 132(2):543-50. PubMed ID: 17258721
[TBL] [Abstract][Full Text] [Related]
6. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
Matsuda M; Suzuki F; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Satoh J; Kobayashi M; Ikeda K; Miyakawa Y; Kumada H
J Med Virol; 2004 Oct; 74(2):361-6. PubMed ID: 15332287
[TBL] [Abstract][Full Text] [Related]
7. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
Kohmoto M; Enomoto M; Tamori A; Habu D; Takeda T; Kawada N; Sakaguchi H; Seki S; Shiomi S; Nishiguchi S
J Med Virol; 2005 Feb; 75(2):235-9. PubMed ID: 15602726
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
Picardi M; Pane F; Quintarelli C; De Renzo A; Del Giudice A; De Divitiis B; Persico M; Ciancia R; Salvatore F; Rotoli B
Haematologica; 2003 Nov; 88(11):1296-303. PubMed ID: 14607759
[TBL] [Abstract][Full Text] [Related]
9. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
[TBL] [Abstract][Full Text] [Related]
10. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
11. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
[TBL] [Abstract][Full Text] [Related]
12. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B.
Lo CM; Liu CL; Chan SC; Lau GK; Fan ST
J Hepatol; 2005 Aug; 43(2):283-7. PubMed ID: 15964658
[TBL] [Abstract][Full Text] [Related]
13. Association of concurrent hepatitis B surface antigen and antibody to hepatitis B surface antigen with hepatocellular carcinoma in chronic hepatitis B virus infection.
Jang JS; Kim HS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Kim DJ; Lee MS; Park CK; Jeong BH; Kim YS; Jang MK
J Med Virol; 2009 Sep; 81(9):1531-8. PubMed ID: 19623669
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of lamivudine-resistant hepatitis B virus (HBV) strains with and without breakthrough hepatitis in patients with chronic hepatitis B evaluated by serial HBV full-genome sequences.
Horiike N; Duong TN; Michitaka K; Joko K; Hiasa Y; Konishi I; Yano M; Onji M
J Med Virol; 2007 Jul; 79(7):911-8. PubMed ID: 17516520
[TBL] [Abstract][Full Text] [Related]
15. Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection.
Zhang JM; Xu Y; Wang XY; Yin YK; Wu XH; Weng XH; Lu M
Clin Infect Dis; 2007 May; 44(9):1161-9. PubMed ID: 17407033
[TBL] [Abstract][Full Text] [Related]
16. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
17. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
[TBL] [Abstract][Full Text] [Related]
18. Prolonged persistence of lamivudine-resistant mutant and emergence of new lamivudine-resistant mutants two years after lamivudine withdrawal in HBsAg-positive chronic hepatitis patient: a case report.
Orlando R; Tosone G; Portella G; Veropalumbo E; D'Onofrio M; Piazza M
Infection; 2008 Oct; 36(5):472-4. PubMed ID: 17962902
[TBL] [Abstract][Full Text] [Related]
19. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.
Pollicino T; Isgrò G; Di Stefano R; Ferraro D; Maimone S; Brancatelli S; Squadrito G; Di Marco V; Craxì A; Raimondo G
Antivir Ther; 2009; 14(5):649-54. PubMed ID: 19704167
[TBL] [Abstract][Full Text] [Related]
20. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
